· Turning on the ‘off switch’ in cancer cells →
The discovery marks a critical step toward developing a potential new class of anti-cancer drugs that enhance the activity of a prevalent family of tumor suppressor proteins, the authors say.
· Guardant Health: A Rising Star →
It is a non-invasive alternative to surgical biopsies that enables doctors to discover a range of information about any disease or a tumor through a blood sample.
The New York Times
· Why Is Boris Johnson Defending Dominic Cummings? →
He once said that members of a hard-line pro-Brexit caucus in Parliament, the European Research Group, “should be treated like a metastasizing tumor and excised from the U.K. body politic.”
· Epizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced →
In FL, EPZM's clinical trial showed significant complete and partial responses noting independent review committee said Tazverik demonstrated tumor reduction in 98% (44 of 45 patients) trial participants.
· FDA OKs expanded use of Bristol Myers' Opdivo + Yervoy in first-line lung cancer →
Under its Real-Time Oncology Review pilot program, the FDA has approved Bristol Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) 360 mg + Yervoy (ipilimumab) 1 mg/kg with two cycles of platinum-doublet chemotherapy for the first-line treatment of metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
· Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma →
To confirm these findings, the researchers conducted a larger, multicenter phase 2 study, enrolling 113 patients identified as having low- or high-risk disease, based on characteristics such as tumor bulk and performance status.
· Deep learning accurately stains digital biopsy slides →
“Our development of a de-staining tool may allow us to vastly expand our capacity to perform research on millions of archived slides with known clinical outcome data,” says Alarice Lowe, an associate professor of pathology and director of the Circulating Tumor Cell Lab at Stanford University, who was a co-author on the paper.
· Study reveals first evidence inherited genetics can drive cancer’s spread →
It has long been suspected that genetic mutations arising inside tumor cells drive this potentially devastating turn of events.